Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone/Salmeterol Respirent vs Seretide Diskus
NCT03894280Phase 1Completed
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate nasal spray and salmeterol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration and Maximum plasma concentration. Started Mar 2019; status: completed.
02
Drugs
fluticasone propionate nasal spraysalmeterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03894280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894280.